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This study aimed to assess the correlation of temporal muscle thickness (TMT), measured
on routine cranial magnetic resonance (MR) images, with lumbar skeletal muscles obtained
on computed tomography (CT) images in brain metastasis patients to establish a new
parameter estimating skeletal muscle mass on brain MR images.
Methods
We retrospectively analyzed the cross-sectional area (CSA) of skeletal muscles at the level
of the third lumbar vertebra on computed tomography scans and correlated these values
with TMT on MR images of the brain in two independent cohorts of 93 lung cancer and 61
melanoma patients (overall: 154 patients) with brain metastases.
Results
Pearson correlation revealed a strong association between mean TMT and CSA in lung cancer
and melanoma patients with brain metastases (0.733; p<0.001). The two study cohorts did not
differ significantly in patient characteristics, including age (p = 0.661), weight (p = 0.787), and
height (p = 0.123). However, TMT and CSA measures differed significantly between male and
female patients in both lung cancer and melanoma patients with brain metastases (p<0.001).
Conclusion
Our data indicate that TMT, measured on routine cranial MR images, is a useful surrogate
parameter for the estimation of skeletal muscle mass in patients with brain metastases.
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Thus, TMT may be useful for prognostic assessment, treatment considerations, and stratifi-
cation or a selection factor for clinical trials in patients with brain metastases. Further studies
are needed to assess the association between TMT and clinical frailty parameters, and the
usefulness of TMT in patients with primary brain tumors.
Introduction
Sarcopenia is defined as a reduction of skeletal muscle mass and function.[1,2] It was first used
to describe age-related muscle mass loss in the elderly population.[1] Secondary causes for sar-
copenia are diverse, and include malnutrition, chronic disease, and cancer.[3] Moreover, sar-
copenia has an important role in cancer-related cachexia, which has been defined by an
international committee as a syndrome, which consists of skeletal muscle mass loss associated
with increasing functional impairment that is not reversible by conventional nutrition supple-
mentation.[4] Sarcopenic cancer patients are known to have a poorer outcome with regard to
postoperative complications, tumor progression time, and overall survival.[5–6] Dual-energy
X-ray absorptiometry (DXA) is an established method to precisely evaluate human body com-
position.[7] Mourtzakis et al. showed a high correlation between the skeletal muscle mass as
assessed by DXA and the skeletal muscle cross-sectional area (CSA) at the level of the third
lumbar vertebra obtained by computed tomography (CT) images.[8] Moreover, they presented
sex-specific cut-off values to determine sarcopenia for the lumbar CSA adjusted to patient
height representing a skeletal muscle index (SMI).[5,9] Based on this study, sarcopenia has
been determined by an international consensus as a SMI of� 55 cm2/m2 for men and� 39
cm2/m2 for women, although the sex-specific SMI cut-off values vary in the literature.
[4,5,8,10] However, in patients with brain metastases, CT examinations at the level of the third
lumbar vertebra are not always available. Performing dual-energy X-ray absorptiometry tech-
nique or CT scans solely in order to assess or estimate skeletal muscle mass would lead to an
increased radiation dose for the patients, as well as additional healthcare costs.
Recently published papers indicate that, in addition to lumbar skeletal muscles, craniofacial
skeletal muscles are also useful for the assessment of muscle mass loss.[11,12] This would be
advantageous, especially in patients with brain tumors, in which abdominal CT scans are often
not available.
Swartz et al. revealed that the cross-sectional area of skeletal muscles at the level of the third
cervical vertebra, obtained by head and neck CT images, can assess sarcopenia in head and
neck cancer patients.[11] Ranganathan K et al. demonstrated a correlation between the psoas
muscle area and temporal muscle thickness (TMT).[12] Moreover, we showed recently that
TMT allows survival prediction in patients with newly diagnosed brain metastases.[13]
The purpose of this study was to investigate whether TMT, obtained on routine magnetic
resonance (MR) images of the brain correlates with CSA of skeletal muscles, assessed on CT
images at the level of the third lumbar vertebra, and thus, may be used to estimated skeletal
muscle mass in patients with brain metastases.
Methods
Patients
Patients of the Medical University of Vienna with brain metastases from either lung cancer or
melanoma between 2002 and 2014 were identified from a brain metastasis database. Inclusion
criteria were (a) an MR examination of the brain and an abdominal CT scan of the same
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patient within one month, and (b) assessable information about a patient‘s weight and height
within one month of the imaging examination. Lung cancer and melanoma patients were
selected for this investigation because those tumor entities are prone to spread to the CNS and
do receive CT scans of the abdomen for tumor staging at our institution.[14,15]
We could include 93 lung cancer and 61 melanoma patients in this study (total: n = 154
patients). The study was approved by the ethics committee of the Medical University of Vienna
(Vote 1538/2017; 1551/2017). Written informed consent was waived by the ethics committee
due to the retrospective design of the study. All patient records used in this study were anon-
ymized before data assessment.
Analyses of TMT on brain MR images
TMT was measured manually on a picture archiving and communication system (PACS).
Measurements were taken perpendicularly to the long axis of the temporal muscle on con-
trast-enhanced isovoxel 1 x 1 x 1 mm T1-weighted MR images without fat-saturation obtained
by 1,5 Tesla or 3 Tesla MRI scanners. The MR plane was oriented axial, parallel to the anterior
commissure–posterior commissure line. The measurements were taken at the level of the
orbital roof, and the Sylvian fissure was defined as a reference point regarding the anterior-
posterior orientation. TMT was evaluated on the left and on the right side separately, in all
included patients, by a board-certified radiologist (JF) blinded to the results of CSA on abdom-
inal CT images and to all clinical characteristics. The TMT measurements of each side were
summed and divided by two, resulting in a mean TMT per patient.
Analyses of CSA on abdominal CT images
The CSA of the lumbar skeletal muscles was evaluated on venous-phase CT images of the
abdomen. A single slice was manually selected on the level of the third lumbar vertebra where
both transverse processes were depicted. The open-source image processing program NIH
ImageJ was used for further image analysis.[16] To assess the CSA of the skeletal muscles and
exclude visceral organs and adipose tissue at this level, a semi-automated, specific tissue seg-
mentation was performed using the Hounsfield unit thresholds from -29 to + 150.[5,6] Falsely
demarcated structures were manually corrected. To calculate the SMI, CSA values were
divided by the square of patient height as previously defined in the literature.[5,8]
Examples of TMT on brain MR images and CSA measurements on CT scans at the level of
the third vertebra are provided in Fig 1.
Statistical analysis
Age, TMT, CSA, SMI, and patient weight and height of the two different patient groups were
compared using an independent-samples t-test.
To correlate TMT with CSA, SMI, and patient weight and height, a Spearman correlation coef-
ficient was used. A correlation coefficient of (-)0.8 to (-)1 was interpreted as a very strong associa-
tion, of (-)0.6–0.8 as strong, of (-)0.4 to (-)0.6 as moderate, and of (-)0.2 to (-)0.4 as a low
association. There was no association for a correlation coefficient of 0 to (-)0.2. A Mann-Whitney-
U-Test was used to reveal differences between sarcopenic and non-sarcopenic patient cohorts.
ROC Analysis was used to reveal TMT cut-off measures based on sex-specific SMI cut-off values.
Intra-rater and inter-rater reliability was assessed for the lung-cancer sub-cohort patients
(n = 93) using Cronbach’s alpha.
Statistical analyses were performed using the Statistical Package for the Social Sciences, Ver-
sion 24.0 (SPSS, Chicago, Illinois). Parametric testing was used to compare groups.
A two-tailed p-value of< 0.05 was considered statistically significant.
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Results
Patient characteristics
Overall, 154 patients were available for further analysis, assembled from two independent
cohorts that consisted of 93 patients with brain metastases from lung cancer and 61 patients
with brain metastases from melanoma. Patient age, sex, height, and weight measures between
the two different patient groups did not differ significantly (please see Table 1 for descriptive
measures).
Assessment of TMT, CSA and SMI
In lung cancer patients, the mean TMT was 6.1 mm (range, 2.8–9.3 mm), and the mean TMT
in melanoma patients was 6.2 mm (range, 2.8–10.9 mm). There was no statistically significant
Fig 1. Examples of CSA measurements on CT images (A, C) and TMT measurements on brain MR images (B, D) in two melanoma
patients with brain metastases. A, B, a male patient with an estimated normal skeletal muscle mass (mean CSA = 191.61 mm2; mean
TMT = 7.3 mm) and C,D, a female patient with considerable estimated skeletal muscle mass loss (mean CSA = 106.07 mm2; mean
TMT = 4.5 mm).
https://doi.org/10.1371/journal.pone.0207849.g001
Temporal muscle thickness and skeletal muscle mass
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difference in the TMT in these two tumor entities (p = 0.661). The mean TMT differed signifi-
cantly (p<0.001) between male (7.0 mm; range, 3.8–10.8 mm) and female (5.2 mm; range 2.8–
8.5 mm) patients in both study cohorts.
The mean CSA was 130.1 cm2 (range, 65.6–208.0 cm2) in lung cancer patients and 136.5
cm2 (range, 78.8–205.3 cm2) in melanoma patients. No statistical difference with regard to the
CSA was observed in lung cancer or melanoma patients (p = 0.221). However, the mean CSA
showed a significant sex-specific difference (p<0.001), with a mean CSA of 106.10cm2 (range,
65.6–138.9 cm2) in female and 154.2 cm2 (range, 94.13–208.0 cm2) in male patients of both
study cohorts.
The mean SMI in lung cancer patients was 43.96 cm2/m2 (range, 24.70–65.85 cm2/m2) and
the mean SMI in melanoma patients was 45.20 cm2/m2 (range, 27.28–63.35 cm2/m2). No sta-
tistical difference with regard to the SMI was observed in lung cancer patients and melanoma
patients (p<0.359). The mean SMI differed significantly (p<0.001) between male (48.51cm2/
m2, range, 27.64–65.85 cm2/m2) and female (39.46 cm2/m2, range 24.70–58.13 cm2/m2)
patients in both study cohorts. For detailed information see also S1 Table.
After dividing the whole study cohort in sarcopenic (male, n = 65; female, n = 35) and non-
sarcopenic (male, n = 20; female, n = 34) patients using a sex-specific cut-off SMI value
(39cm2/m2 for female patients and 55 cm2/m2) the associated TMT values differed signifi-
cantly between sarcopenic and non-sarcopenic male (p = 0.004) and female (p = 0.001)
patients, respectively.[4]
Correlation of TMT with CSA and SMI
The correlation between TMT and CSA as well as TMT and SMI in melanoma and lung cancer
patients with brain metastases is shown in Fig 2 and Fig 3.
The mean TMT showed a highly significant correlation with CSA in both groups (Spear-
man correlation coefficient 0.733; p<0.001), as well as in the melanoma subgroup (Spearman
correlation coefficient 0.692; p<0.001) and lung cancer subgroup (Spearman correlation coef-
ficient 0.767; p<0.001) separately.
The association of mean TMT with SMI values was also highly significant in the melanoma
subgroup (Spearman correlation coefficient 0.650; p<0.001) and in the lung cancer subgroup
(Spearman correlation coefficient 0.662; p<0.001) resulting in an overall Spearman correlation
coefficient between TMT and SMI of 0.655; p<0.001 in both cohorts.
Correlation of TMT with clinical parameters
The Pearson correlation revealed a moderate association between patient height and TMT
measurements in both study groups (Spearman correlation coefficient 0.504; p<0.001). Patient
weight showed a low correlation with TMT in the whole study population (Spearman correla-
tion coefficient 0.385; p<0.001). Furthermore, a low negative correlation was detected between
Table 1. Descriptive statistics for patient sex, age, height, and weight.
Melanoma Lung cancer p-value
Number of patients 61 93 n.a.
Female 25 (41%) 49 (53%) n.a.
Male 36 (59%) 44 (47%) n.a.
Age (mean ± SD, in years) 60.1 (±15.8) 61.5 (±8.3) 0.661
Weight (mean ± SD, in kg) 77.0 (±13.6) 76.3 (±17.0) 0.787
Height (mean ± SD, in m) 1.73 (±0.1) 1.71 (±0.1) 0.123
https://doi.org/10.1371/journal.pone.0207849.t001
Temporal muscle thickness and skeletal muscle mass
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TMT and the age at diagnosis of brain metastasis for all patients included in this study (Spear-
man correlation coefficient –0.246; p = 0.002).
Assessment of inter- and intra-rater agreement
Intra-rater and intra-rater reliability was assessed for the lung-cancer sub-cohort patients
(n = 93) using Cronbach’s alpha resulting in a next to perfect intra-rater agreement (left TMT
0.959; right TMT 0.975) and intra-rater agreement (left TMT 0.917; right TMT 0.94).
Fig 2. Correlation between CSA of the skeletal muscles at the third lumbar vertebra and the mean TMT values in melanoma (☐) and lung cancer (Δ) patients with
brain metastases.
https://doi.org/10.1371/journal.pone.0207849.g002
Temporal muscle thickness and skeletal muscle mass
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Discussion
Sarcopenic cancer patients are known to have an impaired outcome with regard to toxicity
when treated with chemotherapy, more postoperative complications, as well as poorer overall
survival.[5,6,17,18] Therefore, additional information about skeletal muscle mass loss at the
time of disease diagnosis, in combination with other clinical parameters, could influence indi-
vidual treatment decisions or patient selection and stratification in clinical trials. Therefore, we
investigated whether TMT obtained on routine MR images of the brain correlates with CSA of
the skeletal muscles at the level of the third lumbar vertebra and SMI values, through the
Fig 3. Correlation between SMI values and mean TMT values in melanoma (☐) and lung cancer (Δ) patients with brain metastases.
https://doi.org/10.1371/journal.pone.0207849.g003
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evaluation of CT images in two independent cohorts of melanoma and lung cancer patients
with brain metastases to establish a new parameter estimating skeletal muscle mass on brain
MR images. The present study revealed a high correlation between the lumbar skeletal muscle
area and TMT as well as SMI values and TMT. Moreover, TMT values differed significantly
between sarcopenic and non-sarcopenic male (p = 0.004) and female (p = 0.001) patients,
respectively, which indicates that TMT can be used to estimate skeletal muscle mass loss and
may be a surrogate parameter for sarcopenia.
Previously published findings have already revealed that, in addition to abdominal skeletal
muscles, the craniofacial skeletal muscles are also useful for the estimation of muscle mass loss.
Swartz et al. showed that the CSA of the skeletal muscles at the level of the third cervical verte-
bra (including paravertebral muscles and the sternocleidomastoid muscles) highly correlate
with the CSA of the skeletal muscles at the level of the third lumbar vertebra and thus, they
suggested that also cervical skeletal muscles can be used to estimate the skeletal muscle mass in
head and neck cancer patients.[11] Kilgour et al. used the CSA of neck muscles at the level of
the second cervical vertebra to estimate age-related muscle mass loss on brain MR examina-
tions.[19] However, in most routine MR scans of our study population, these muscles were
depicted only partially or not at all. Therefore, we chose the temporal muscle for skeletal mus-
cle mass estimation on routine brain MR images because it is one of the few muscles that are
depicted on routine brain MR images in its full extent. Furthermore, we did not assess a CSA
but rather a one-dimensional measurement to avoid time-consuming volume or plane seg-
mentation. In line with previously published data we could show an almost perfect inter-rater
and intra-rater agreement, using predefined anatomical landmarks, and are very simple and
fast to obtain, at approximately 30 seconds per patient, which makes this technique easily
includable in the daily clinical workflow.[13] In contrast, for the CSA assessment, the images
had to be exported to another workstation to use a semi-automatic segmentation program
(NIH ImageJ) with additional manual correction subsequently, in most cases, which resulted
in an overall acquisition time for CSA of approximately 25 minutes.[16]
TMT measurements were correlated with patient characteristics to investigate the influence
of patient age, height, or weight. Age and weight of the melanoma and lung cancer patients
with brain metastases showed only a low correlation with TMT, and are, therefore, expected
not to have a major impact on TMT values. First, these findings demonstrate that, in cancer
patients, the muscle mass loss is more apparent compared to the known sarcopenic state of
aging alone.[1] Second, the weak correlation between weight and TMT may be due to the fact
that patient weight is not able to differentiate between fat and lean body mass. Therefore, it
might be assumed that, in contrast to patient weight, TMT is more likely to detect sarcopenic
obesity.[5] The mean TMT and CSA differed significantly between male and female patients
in both study cohorts. This is attributable to the sex-specific body composition and compara-
ble to results in previously published papers, which also found significant sex-specific differ-
ences in mean TMT and CSA values in cancer patients.[13]
Previously published data revealed that height showed the strongest correlation with skele-
tal muscle mass and strength among body antropometric measures.[20] These findings are in
line with our results although TMT measurements showed only a moderate association with
patient height. In contrary to indices that estimate skeletal muscle mass based on trunk and
limb muscle, height is hardly supposed to affect cranio-facial muscles and therefore we did not
adjust TMT by height when comparing individuals of different size.[20, 21] Moreover, the
moderate correlation between TMT and patient height is also the reason for the slightly lower
correlation of TMT and SMI (CSA/patient height in m2) in comparison to TMT and CSA.
Although, TMT values differed significantly between sarcopenic and non-sarcopenic
patients no suitable TMT cut-off measure could be defined based on a ROC analysis using sex-
Temporal muscle thickness and skeletal muscle mass
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specific SMI cut-off values. Furthermore, sex-specific SMI cut-off values vary in the literature
with a range from 41,1 cm2/m2 to 39 cm2/m2 and from 43,7 cm2/m2 to 55 cm2/m2 in female
and male patients, respectively.[4,5,10]{Bibliography} Therefore, further prospective studies
are needed to correlate TMT with other clinical frailty parameters of the patients in order to
define sex-specific cut-off values for the determination of sarcopenia using TMT in brain
tumor patients.
A potential limitation of this study is that the assessed diameter of the temporal muscle was
relatively small. Therefore, accurate compliance with the use of predefined anatomical land-
marks is all the more important to guarantee high measurement accuracy as already shown in
a previously published manuscript.[13] Moreover, TMT measurements could be biased by
partial volume artefacts. To minimize partial volume artefacts only patients with isovoxel 1 x 1
x 1mm MR images had been included in this study.
However, the temporal muscle has been chosen because it is one of the few muscles that are
depicted on routine brain MR images in its full extent. This seemed essential to us to exclude
any circumstances, which could influence muscle thickness (e.g. postoperative edema or mus-
cle atrophy).
Another limitation is the retrospective design of this study. As a result, muscular strength
or patient frailty could not be considered. To investigate the correlation of TMT with func-
tional parameters (for example, grip strength), and to determine sex-specific cut-off values for
a diagnosis of sarcopenia, further prospective studies are needed. However, due to the strong
correlation of TMT and CSA of the skeletal muscles of the third lumbar vertebra, our data pro-
vide evidence that TMT is a useful parameter with which to estimate skeletal muscle mass in
brain metastasis patients. This should also be evaluated to determine whether this is also appli-
cable to other brain tumor types, such as gliomas. Furthermore, TMT could be influenced by
oral or dental disease.[22] To overcome this problem, TMT values were measured on both
sides and divided by two to calculated the mean TMT value for each patient and reduce dental
or oral related muscle changes as far as possible.
We conclude that skeletal muscle mass can be estimated on routine brain MR images in
brain metastasis patients and may be used as an alternative to abdominal CT scans. This would
be an advantage for patients where abdominal CT scans are not available to reduce patient
radiation dose, as well as health costs, and may help in treatment or clinical trial selection.
However, further prospective studies designed to correlate TMT with other clinical frailty
parameters are required.
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